CRISPR therapies march into clinic, but genotoxicity concerns linger.
Nature biotechnology, 39(8): 897-899 PMID 34267391 DOI 10.1038/d41587-021-00017-3
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.